

**RESEARCH**
**NIIT Technologies | Target: Rs 1,330 | +12% | ADD**

Good quarter with confident commentary – upgrade to ADD

**Persistent Systems | Target: Rs 530 | +5% | REDUCE**

IP business spoils the show yet again

**Market Strategy | Macro View**

Excise duties on fuel hiked to meet fiscal challenges

**Oil & Gas**

Mar'20 natural gas consumption slips

**SUMMARY**
**NIIT Technologies**

NIIT Tech (NITEC) reported a strong Q4FY20 with 3% QoQ CC revenue growth and resilient operating margins. It secured three large deals and has a healthy executable order book (+20% YoY). Contrary to peers, NITEC expects FY21 to be a growth year but sees 80bps of margin headwinds. We trim FY21/FY22 EPS by 11%/6% on Covid-led demand and profit compression, and lower our Mar'21 TP to Rs 1,330 (from Rs 1,800). Valuation comfort (40% correction in three months), a strong Q4 and confident commentary drive our upgrade from SELL to ADD.

[Click here for the full report.](#)

**Persistent Systems**

Persistent Systems (PSYS) reported a weak Q4FY20 as revenue declined 1.8% QoQ to US\$ 127mn due to a 24% drop in IP revenue. This was the weakest IP revenue show in 35 quarters on an already soft Q3FY20 base. The services (non-IP) business held strong with 4.2% QoQ dollar revenue growth. We cut FY21/FY22 EPS by 29%/16% to bake in pandemic-led challenges and revise our Mar'21 TP to Rs 530 (vs. Rs 650). Retain REDUCE as we remain wary of IP business volatility and subpar expertise in the enterprise business.

[Click here for the full report.](#)

**TOP PICKS**
**LARGE-CAP IDEAS**

Company	Rating	Target
<a href="#">Bajaj Finance</a>	Buy	3,000
<a href="#">Cipla</a>	Buy	570
<a href="#">Eicher Motors</a>	Buy	18,100
<a href="#">GAIL</a>	Buy	140
<a href="#">Petronet LNG</a>	Buy	330

**MID-CAP IDEAS**

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	2,870
<a href="#">Greenply Industries</a>	Buy	145
<a href="#">Laurus Labs</a>	Buy	630
<a href="#">Muthoot Finance</a>	Buy	950
<a href="#">Transport Corp</a>	Buy	255

Source: BOBCAPS Research

**DAILY MACRO INDICATORS**

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.66	3bps	7bps	(179bps)
India 10Y yield (%)	6.07	(1bps)	(23bps)	(131bps)
USD/INR	75.64	0.1	0.7	(8.9)
Brent Crude (US\$/bbl)	30.97	13.9	(9.2)	(55.7)
Dow	23,883	0.6	13.4	(8.0)
Shanghai	2,860	1.3	3.5	(2.3)
Sensex	31,454	(0.8)	14.0	(17.8)
India FII (US\$ mn)	4 May	MTD	CYTD	FYTD
FII-D	(38.9)	(38.9)	(11,382.6)	(1,623.1)
FII-E	(123.3)	(123.3)	(6,756.8)	(153.8)

Source: Bank of Baroda Economics Research

**BOBCAPS Research**

research@bobcaps.in



## Market Strategy: Macro View

The Centre has hiked excise duties on petrol and diesel by Rs 10 and Rs 13 per litre respectively as it strives to balance the fiscal math, translating to an estimated windfall of ~Rs 2tn for the exchequer. These hikes could make up for the shortfall in GST collections arising due to the economic shutdown. But with the government unlikely to meet divestment revenue targets of ~Rs 2tn for FY21, we see a high probability of further increases in excise duty. This could create room for another round of economic stimulus.

[Click here for the full report.](#)

## Oil & Gas

Natural gas consumption in Q4FY20 increased a mere 2.6% YoY to 150mmscmd as offtake inched up across sectors and power demand dropped – CGD (28.6mmscmd, +10% YoY), other industrials (50.6mmscmd, +8.2% YoY) and fertiliser (45.4mmscmd, +4% YoY). Power sector consumption slowed to 26mmscmd (-14% YoY). CGD was the biggest swing factor, improving by 2.6mmscmd YoY during the quarter. However, the economic shutdown curtailed gas consumption in the month of March to ~139mmscmd vs. the average of 156.2mmscmd for Jan-Feb'20.

[Click here for the full report.](#)

**ADD**

TP: Rs 1,330 | ▲ 12%

**NIIT TECHNOLOGIES**

| IT Services

| 06 May 2020

## Good quarter with confident commentary – upgrade to ADD

NIIT Tech (NITEC) reported a strong Q4FY20 with 3% QoQ CC revenue growth and resilient operating margins. It secured three large deals and has a healthy executable order book (+20% YoY). Contrary to peers, NITEC expects FY21 to be a growth year but sees 80bps of margin headwinds. We trim FY21/FY22 EPS by 11%/6% on Covid-led demand and profit compression, and lower our Mar'21 TP to Rs 1,330 (from Rs 1,800). Valuation comfort (40% correction in three months), a strong Q4 and confident commentary drive our upgrade from SELL to ADD.

Ruchi Burde | Seema Nayak

research@bobcaps.in

**Strong quarter:** Revenue grew by 3% QoQ CC despite strong headwinds in the travel sector (-3.1% QoQ in INR terms). Growth was aided by ramp-up of deals won in Q3FY20. Insurance and Other verticals grew 6.8% QoQ and 11.6% QoQ respectively (in INR terms). Efficient and timely cost control rescued profitability, with reported EBITDA margins at 17.8% (-30bps QoQ, +20bps YoY).


**Healthy deal wins:** NITEC bagged three large deals (two from BFSI and one from APAC business outside India), exiting Q4 with a healthy order intake of US\$ 180mn. Management indicated that the deal pipeline going into Q1FY21 looks robust with a changing deal mix – more consolidation, captive unit takeover and employee rebranding deals.

**Bold outlook in challenging times:** Bucking industry trends, NITEC expects FY21 to be a growth year even as Q1FY21 is likely to witness a sequential revenue decline. Management's FY21 outlook counts on (1) ramp-up of recent large deal wins (three in Q4 and four in Q3), (2) a large executable order book (+20% YoY), and (3) continued momentum outside the travel vertical.

Ticker/Price	NITEC IN/Rs 1,190
Market cap	US\$ 970.2mn
Shares o/s	62mn
3M ADV	US\$ 11.0mn
52wk high/low	Rs 2,060/Rs 735
Promoter/FPI/DII	70%/13%/17%

Source: NSE

## STOCK PERFORMANCE



Source: NSE

## KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20P	FY21E	FY22E
Total revenue (Rs mn)	29,914	36,762	41,839	44,997	49,754
EBITDA (Rs mn)	5,012	6,453	7,431	7,765	9,104
Adj. net profit (Rs mn)	2,802	4,089	4,724	4,994	6,096
Adj. EPS (Rs)	45.4	66.2	76.5	80.8	98.7
Adj. EPS growth (%)	3.5	45.9	15.5	5.7	22.1
Adj. ROAE (%)	15.3	20.3	19.4	17.7	19.1
Adj. P/E (x)	26.2	18.0	15.6	14.7	12.1
EV/EBITDA (x)	14.0	10.8	9.1	8.1	6.4

Source: Company, BOBCAPS Research



**REDUCE**

TP: Rs 530 | ▲ 5%

**PERSISTENT SYSTEMS**

| IT Services

| 06 May 2020

**IP business spoils the show yet again**

**Persistent Systems (PSYS) reported a weak Q4FY20 as revenue declined 1.8% QoQ to US\$ 127mn due to a 24% drop in IP revenue. This was the weakest IP revenue show in 35 quarters on an already soft Q3FY20 base. The services (non-IP) business held strong with 4.2% QoQ dollar revenue growth. We cut FY21/FY22 EPS by 29%/16% to bake in pandemic-led challenges and revise our Mar'21 TP to Rs 530 (vs. Rs 650). Retain REDUCE as we remain wary of IP business volatility and subpar expertise in the enterprise business.**

Ruchi Burde | Seema Nayak

research@bobcaps.in


**Continued weak performance in IP segment:** PSYS saw the highest QoQ decline in IP revenues in the last 35 quarters, partly due to seasonality. IBM royalty revenues dropped despite PSYS securing gold partner status. The reseller business is also facing challenges due to structural and leadership changes. Despite induction of an ex-IBM CEO, IP revenues have failed to ramp up over the last year. The Alliance business with IBM needs to be revived by cross-selling, in our view.

**Margins resilient in Q4 but slump in FY20:** Despite a slowdown in the lucrative IP business, Q4 EBITDA margins improved 40bps QoQ to 13.8%, aided by 30bps of currency-led tailwinds. But FY20 margins at 13.8% contracted 340bps due to higher sales, marketing and employee costs. Management is hopeful of recovery supported by the absence of some one-time costs and rebranding expenses (US\$ 1.5mn). We see downside risk to FY21 margin recovery targets given a weak demand outlook and increasing requests for concessions from clients struggling with Covid-19 challenges.

**Retain REDUCE:** We trim FY21/FY22 earnings estimates by 29%/16%, pare our target FY22E P/E multiple to 11.3x (vs. 12.5x earlier) baking in Covid-led uncertainty, and revise our TP to Rs 530.

Ticker/Price	PSYS IN/Rs 505
Market cap	US\$ 531.7mn
Shares o/s	80mn
3M ADV	US\$ 0.8mn
52wk high/low	Rs 740/Rs 420
Promoter/FPI/DII	30%/26%/44%

Source: NSE

**STOCK PERFORMANCE**

Source: NSE

**KEY FINANCIALS**

Y/E 31 Mar	FY18A	FY19A	FY20P	FY21E	FY22E
Total revenue (Rs mn)	30,337	33,659	35,658	37,181	41,749
EBITDA (Rs mn)	4,687	5,805	4,930	5,537	6,635
Adj. net profit (Rs mn)	3,231	3,516	3,403	2,972	3,766
Adj. EPS (Rs)	40.4	43.9	42.7	37.3	47.2
Adj. EPS growth (%)	7.1	8.8	(2.9)	(12.7)	26.7
Adj. ROAE (%)	16.0	15.7	14.1	11.5	13.5
Adj. P/E (x)	12.5	11.5	11.8	13.5	10.7
EV/EBITDA (x)	8.3	6.6	7.8	7.0	5.7

Source: Company, BOBCAPS Research



## MACRO VIEW

06 May 2020

### Excise duties on fuel hiked to meet fiscal challenges

The Centre has hiked excise duties on petrol and diesel by Rs 10 and Rs 13 per litre respectively as it strives to balance the fiscal math, translating to an estimated windfall of ~Rs 2tn for the exchequer. These hikes could make up for the shortfall in GST collections arising due to the economic shutdown. But with the government unlikely to meet divestment revenue targets of ~Rs 2tn for FY21, we see a high probability of further increases in excise duty. This could create room for another round of economic stimulus.

Rohit Ahuja | Harleen Manglani

research@bobcaps.in

**Government eyeing >Rs 4tn windfall from oil price crash:** As highlighted in our [Mar'20 report](#), the government has begun to benefit from low oil prices via (1) a ~Rs 15/ltr hike in excise duties on petrol/diesel (yielding ~Rs 2tn in additional revenues for FY21), and (2) savings on petroleum subsidies (budgeted at Rs 350bn for FY21). The Centre could target cumulative gains of ~Rs 4tn in order to neutralise potentially lower GST collections and divestment revenues, implying a further excise hike of Rs 10/ltr in FY21.

**Indirect tax hikes only way to meet capex targets:** With the heavy economic damage inflicted by Covid-19, it is imperative for the government to maintain capex targets (budgeted estimate of ~Rs 4tn for FY21) to support a revival in GDP growth. Thus, it may move into politically unpopulist territory comprising steep taxes on fuel (and liquor) to maintain the fiscal balance. Since consumption revival is the need of the hour, GST hikes on consumer products could be counterproductive.

**Room for more stimulus:** The government's initial round of stimulus (Rs 1.7tn), followed up by >Rs 3tn in liquidity inducement measures by the RBI are clearly falling short. As per [media reports](#), plans for additional stimulus to prop up MSMEs are also on the anvil. The current excise duty hikes could open up the headroom to facilitate such measures.

**FIG 1 – EXCISE DUTY**

(Rs/ltr)	Basic excise duty	Special additional excise duty	Additional excise duty (Road & Infra cess)	Expected revenues (Rs bn)
Petrol	2.98	10	10	9,200
Petrol (revised)	2.98	12	18	13,200
Diesel	4.83	4	10	19,000
Diesel (revised)	4.83	9	18	34,000
<b>Earlier estimate</b>				<b>28,200</b>
<b>Revised estimate</b>				<b>47,200</b>

Source: BOBCAPS Research, PPAC

**BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda**

Important disclosures, including any required research certifications, are provided at the end of this report.



## OIL &amp; GAS

06 May 2020

**Mar'20 natural gas consumption slips**

**Consumption gains pre-crisis pared in March:** Natural gas consumption in Q4FY20 increased a mere 2.6% YoY to 150mmscmd as offtake inched up across sectors and power demand dropped – CGD (28.6mmscmd, +10% YoY), other industrials (50.6mmscmd, +8.2% YoY) and fertiliser (45.4mmscmd, +4% YoY). Power sector consumption slowed to 26mmscmd (-14% YoY). CGD was the biggest swing factor, improving by 2.6mmscmd YoY during the quarter. However, the economic shutdown curtailed gas consumption in the month of March to ~139mmscmd vs. the average of 156.2mmscmd for Jan-Feb'20.

**Offtake from fertiliser, power and CGD dip:** Fertiliser, power and CGD demand in Mar'20 declined by 5.4mmscmd, 5mmscmd and 5.3mmscmd YoY respectively, far below the average consumption registered during Jan'20 and Feb'20. Refineries and petrochemicals were less affected with offtake down by 0.3mmscmd on average from both sectors in March.

**Domestic gas production declines:** Gas production slipped 8% YoY to 83mmscmd during Mar'20, with the biggest decline of 30% YoY to 10.1mmscmd seen with private players. ONGC and OILN also reduced production on average during Q4FY20 at 65.5 mmscmd (-6% YoY) and 7mmscmd (-5% YoY) respectively. This trend would worsen in Q1FY21 given disruptions in demand due to the economic slowdown.

**FIG 1 – GAS CONSUMPTION**

(mmscmd)	Q4FY20	Q4FY19	YoY (%)	Q3FY20	QoQ (%)	FY20	FY19	YoY (%)
Fertiliser	45.4	43.7	3.9	45.7	(0.8)	43.9	41.3	6.4
Power	25.9	30.1	(14.1)	28.4	(8.7)	30.3	32.5	(6.8)
CGD	28.6	26.0	9.9	30.1	(5.0)	28.6	25.3	13.4
Other industrials:	50.5	46.7	8.2	49.9	1.3	50.4	48.7	3.6
Refineries	22.9	18.5	23.7	21.5	6.3	21.3	19.3	10.7
Petrochemicals	9.7	9.4	2.9	9.3	4.3	9.7	9.3	5.1
Miscellaneous	18.0	18.8	(4.3)	19.1	(5.9)	19.3	20.1	(4.0)
<b>Total</b>	<b>150.4</b>	<b>146.5</b>	<b>2.6</b>	<b>154.1</b>	<b>(2.4)</b>	<b>153.2</b>	<b>147.7</b>	<b>3.7</b>

Source: PPAC, BOBCAPS Research

Rohit Ahuja | Harleen Manglani

research@bobcaps.in

**KEY RECOMMENDATIONS**

Ticker	Price	Target	Rating
GAIL IN	94	140	BUY
PLNG IN	233	330	BUY
IGL IN	469	433	BUY
MAHGL IN	895	750	ADD
GUJS IN	195	275	BUY
GUJGA IN	235	265	BUY

Price &amp; Target in Rupees

**GAS CONSUMPTION**

(mmscmd)	Mar'20	Mar'19	YoY (%)
<b>Fertiliser</b>			
Domestic	15.9	19.3	(17.7)
R-LNG	25.9	24.3	6.6
<b>Total</b>	<b>41.8</b>	<b>43.6</b>	<b>(4.1)</b>
<b>Power</b>			
Domestic	17.8	22.0	(19.3)
R-LNG	4.8	6.4	(25.1)
<b>Total</b>	<b>22.6</b>	<b>28.5</b>	<b>(20.6)</b>
<b>CGD</b>			
Domestic	12.1	15.2	(20.3)
R-LNG	12.9	10.2	27.3
<b>Total</b>	<b>25.1</b>	<b>25.4</b>	<b>(1.3)</b>
<b>Other Industrials</b>			
Domestic	11.0	15.2	(27.4)
R-LNG	38.2	31.9	19.9
<b>Total</b>	<b>49.2</b>	<b>47.0</b>	<b>4.7</b>
<b>Total Consumption</b>	<b>138.6</b>	<b>144.5</b>	<b>(4.0)</b>
<b>Total R-LNG</b>	<b>81.9</b>	<b>72.7</b>	<b>12.5</b>
<b>Total Domestic</b>	<b>56.8</b>	<b>71.7</b>	<b>(20.8)</b>

Source: PPAC, BOBCAPS Research



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 30 April 2020, out of 91 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 57 have BUY ratings, 17 have ADD ratings, 9 are rated REDUCE, 7 are rated SELL and 1 is UNDER REVIEW. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.